Stammdaten
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Unternehmen & Branche
| Name | Enveric Biosciences, Inc. |
|---|---|
| Ticker | ENVB |
| CIK | 0000890821 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,1 Mio. USD |
| Beta | 0,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -8,771,987 | -36.24 | 5,095,941 | 4,177,541 | |
| 2025-09-30 | 10-Q | -1,873,669 | -10.81 | 4,362,061 | 3,456,176 | |
| 2025-06-30 | 10-Q | -2,519,181 | -0.97 | 3,548,454 | 2,184,769 | |
| 2025-03-31 | 10-Q | -2,184,966 | -1.22 | 5,102,119 | 3,917,713 | |
| 2024-12-31 | 10-K | -9,574,987 | -228.48 | 3,082,543 | 1,592,807 | |
| 2024-09-30 | 10-Q | -2,084,032 | -43.10 | 4,790,316 | 3,951,150 | |
| 2024-06-30 | 10-Q | -1,879,394 | -3.72 | 6,051,604 | 5,406,264 | |
| 2024-03-31 | 10-Q | -2,456,915 | -9.21 | 8,849,794 | 6,481,856 | |
| 2023-12-31 | 10-K | -17,291,732 | -121.29 | 4,299,840 | 1,956,336 | |
| 2023-09-30 | 10-Q | -2,822,216 | -1.30 | 6,619,194 | 2,435,646 | |
| 2023-06-30 | 10-Q | -6,356,053 | -3.04 | 9,800,170 | 4,874,570 | |
| 2023-03-31 | 10-Q | -4,677,527 | -2.31 | 15,852,474 | 10,405,880 | |
| 2022-12-31 | 10-K | -18,471,333 | -13.00 | 19,552,925 | 14,671,924 | |
| 2022-09-30 | 10-Q | -2,478,912 | -1.46 | 30,855,410 | 22,840,286 | |
| 2022-06-30 | 10-Q | -2,790,505 | -2.73 | 28,572,029 | 21,965,393 | |
| 2022-03-31 | 10-Q | -4,524,014 | 32,179,012 | 24,441,698 | ||
| 2021-12-31 | 10-K | -48,976,896 | 26,719,133 | 22,305,920 | ||
| 2021-09-30 | 10-Q | -2,712,406 | 69,757,704 | 55,366,849 | ||
| 2021-06-30 | 10-Q | -908,289 | 23,694,969 | 18,818,988 | ||
| 2021-03-31 | 10-Q | -3,250,711 | 25,786,625 | 18,991,678 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.